Sign in to view content

Evaluating Intravitreal ANX007, a Novel C1q Inhibitor, in the Treatment of GA Secondary to AMD: The ARCHER Study

David S. Boyer, MD

Video
Published 2021

Related

Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy
Michael J Allingham, MD, PhD
Annual Meeting Talks
2022
12-Month Results of EYP-1901 Vorolanib in a Bioerodible Durasert Insert for nAMD: The DAVIO Trial
Rishi P. Singh, MD
Updates from the Field
2022
E27- DRCR Protocol V Results- Anti-VEGF vs Focal Laser vs Observation for DME in Eyes with Very Good Vision- Dr. Jennifer Sun
Keyvan Koushan, MD, FRCSC
Member Podcasts

Category: AMD-Non-Neovascular

See more